Secukinumab Therapy in Refractory Juvenile Idiopathic Arthritis.

ABSTRACT: Juvenile idiopathic arthritis (JIA), the most common chronic rheumatologic condition in childhood, remains a cause of significant morbidity, particularly in those with spondyloarthropathy, including psoriatic arthritis (PsA) and enthesitis-related arthritis (ERA). While secukinumab was recently approved for the treatment of children and adolescents with ERA and PsA, there is limited published data on its use in JIA, particularly in refractory cases, despite its efficacy in the treatment of adult arthritis. We aim to examine the use of this therapy in JIA in a single pediatric rheumatology center. A retrospective chart review was performed and 10 JIA patients who received treatment with secukinumab were identified. Data extracted included disease activity, patient demographics, comorbiditie

SUBMITTER: Nelson MC 

PROVIDER: S-EPMC10515513 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature